Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 4/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8343039 | 1.00 | AKR1C1 (0.52) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL8215241 | 0.89 | POLB (0.50) | AKR1C1PTGS2KMT2AALDH1A1MEN1 | |
| SCHEMBL13456929 | 0.86 | CES2 (0.47) | AKR1C1AKR1C2AKR1C3KMT2AALDH1A1 | |
| SCHEMBL10425749 | 0.85 | AKR1C1 (0.40) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL367696 | 0.81 | AKR1C1 (0.61) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL1996918 | 0.81 | AKR1C1 (0.61) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL2555171 | 0.81 | AKR1C1 (0.61) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL14638944 | 0.80 | AKR1C1 (0.52) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL28796389 | 0.80 | AKR1C1 (0.52) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A | |
| SCHEMBL14638943 | 0.80 | AKR1C1 (0.52) | AKR1C1AKR1C2AKR1C3PTGS2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORP (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4573090-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2025-06-25 | — | — | EP | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2025049419-A1 | PYRAZOLYL COMPOUNDS AS EMOPAMIL BINDING PROTEIN INHIBITORS | GENZYME CORPORATION (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20250064809-A1 | Inhibitors of Mutant RET Kinases for use in Treating Cancer | STEMLINE THERAPEUTICS, INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-12180211-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-12129263-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2024-10-29 | — | — | US | disclosed |
| EP-4448526-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2016094846-A1 | INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160087213-A1 | ORGANIC ELECTRONIC ELEMENT COMPRISING FULLERENE DERIVATIVE | LG CHEM, LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| EP-2975663-A1 | ORGANIC ELECTRONIC ELEMENT COMPRISING FULLERENE DERIVATIVE | LG Chem, Ltd. (KR) | 2016-01-20 | — | — | EP | disclosed |
| US-20150203879-A1 | Methods and Microorganisms for the Biological Synthesis of (S) -2-amino-6-hydroxypimelate, Hexamethylenediamine and 6-aminocaproate | LCY BIOSCIENCES INC. (CA) | 2015-07-23 | — | — | US | disclosed |
| US-7491743-B2 | Inhibitors of cellular necrosis | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050119260-A1 | Inhibitors of cellular necrosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-06-02 | — | — | US | disclosed |
| US-5968360-A | ADDING A NONTOXIC TERPENE COMPOUND TO CONTAMINATED SOIL TO INDUCE MICROBIAL COMETABOLISM OF CHLORINATED BIPHENYLS; IN SITU BIOREMEDIATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0032548-B1 | PROCESS FOR PREPARING ARYL AND HETEROARYL HEXADIENOIC ACIDS | Montedison S.p.A. (IT) | 1983-06-22 | — | — | EP | disclosed |
| US-4355168-A | Process for preparing aryl- or heteroarylhexadienoic acids | MONTEDISON S.P.A. (IT) | 1982-10-19 | — | — | US | disclosed |
| EP-0032548-A1 | Process for preparing aryl and heteroaryl hexadienoic acids | Montedison S.p.A. (IT) | 1981-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12180211-B2 | Compounds, compositions and methods | BAX, CASP3, CASP8 | AKR1C1 3249/4885AKR1C2 2920/4885AKR1C3 2224/4885 |
| US-20250011338-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | AKR1C1 3937/4885AKR1C2 3795/4885AKR1C3 3908/4885 |
| US-20050119260-A1 | Inhibitors of cellular necrosis | TNF, AIFM1, BAD | AKR1C1 2436/4885AKR1C2 2420/4885AKR1C3 1880/4885 |
| US-20250064809-A1 | Inhibitors of Mutant RET Kinases for use in Treating Cancer | RET, BRAF, HRAS | AKR1C1 3754/4885AKR1C2 3557/4885AKR1C3 3957/4885 |
| US-20250282782-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | PTPN5, PTPN2, PTPRJ | AKR1C1 4680/4885AKR1C2 4561/4885AKR1C3 4681/4885 |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | AKR1C1 4324/4885AKR1C2 4287/4885AKR1C3 4477/4885 |
| US-12129263-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | AKR1C1 3937/4885AKR1C2 3795/4885AKR1C3 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.